Daniel Auclair, President at Hematocure, LLC, posted on X:
“With almost 1,000 myeloma-related communications at this ASH25, it is now impossible to come up with a “Top 10 abstracts” list. Here are 10 topics I found interesting and speak to the continued progress in the mmsm field on bright display this year.
1- The next generation getting closer to the finish line:
- Anito-cel
- CelMoDs
- Tal-Tec combo: redirectt-1
2- Creative approaches
3- Rise of the trispecifics (with JNJ’5322/Ramantamig leading the charge)
And more
Abstract Title: Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody
targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma
Abstract Title: MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple
myeloma (RRMM): Updated results from a Phase 1 dose escalation study
Abstract Title: QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with
relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase Ⅰa study
Abstract Title: Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the
treatment of relapsed/refractory multiple myeloma
4- Dual-targeting CARs – Dr. Shambavi Richard Icahn School of Medicine at Mount Sinai AZD0120
5- Novel WGS-based LB approaches to support new IMS-IMWG HR definition
Abstract Title: Ultra-deep whole-genome sequencing of cell-free DNA recovers most bone marrowderived mutations in newly diagnosed multiple myeloma
Abstract Title: Transitioning from FISH to NGS for immunoglobulin translocation detection in multiple
myeloma
Abstract Title: Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in
high-risk smoldering multiple myeloma
6-Optimal Bridging to CARTs Talq
Abstract Title: Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor Tcell in Relapsed/Refractory multiple myeloma
Abstract Title: Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene
autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma
Abstract Title: Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and
adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)
Abstract Title: Bridging therapy response and low pre-lymphodepletion plasma cell burden are
associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma
Abstract Title: Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory
multiple myeloma: Real-world outcomes in an underserved urban population
7- Continued progress with BCMA-targeting agents in AL Amyloidosis
8-First report of dual bispecific antibody-refractory patients. We better get ready to molecularly profile prior to bispecific treatment. And we need to push these innovative trials looking at time-limited bispecific therapy.
Abstract Title: Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma:
Real-world outcomes and first report of dual bispecific antibody-refractory patients
9- CART or bispecific? Real-world comparison of PFS and OS between ide-cel and teclistamab in triple-class exposed RRMM
Abstract Title: Real-world comparison of progression-free and overall survival between idecabtagene
vicleucel (ide-cel) and teclistamab in triple-class exposed relapsed/refractory multiple myeloma
10- CTCs are powerful risk predictors
More posts featuring Daniel Auclair on OncoDaily.